• PDF / 527,522 Bytes
• 2 Pages / 595.276 x 790.866 pts Page_size
• 49 Downloads / 225 Views

DOWNLOAD

REPORT

CORRECTION

Correction to: Romosozumab: A Review in Postmenopausal Osteoporosis Julia Paik1 · Lesley J. Scott1

© Springer Nature Switzerland AG 2020

Correction to: Drugs & Aging https​://doi.org/10.1007/s4026​6-020-00793​-8

teriparatide in STRU​CTU​RE (p ≤ 0.001) [13], but higher than with alendronate in ARCH (p 

Recommend Documents

Romosozumab: A Review in Postmenopausal Osteoporosis

152 95 983KB

Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare

148 53 209KB

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

167 74 352KB

Adherence to the dietary approaches to stop hypertension (DASH) dietary pattern and osteoporosis risk in postmenopausal

161 5 478KB

Persistence and adherence to parenteral osteoporosis therapies: a systematic review

144 19 784KB

Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis pati

136 26 367KB

Correction to: A Review of Pandemics

148 46 13MB

Correction to: Persistent nepotism in peer-review

166 78 390KB

Correction to: Injuries in Field Hockey Players: A Systematic Review

175 77 288KB

Correction to: Secukinumab: A Review in Ankylosing Spondylitis

181 108 241KB

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

149 90 754KB

Executive functions predict fracture risk in postmenopausal women assessed for osteoporosis

175 86 613KB